Vivos Therapeutics Inc. (NASDAQ: VVOS) witnessed a sharp rally on Friday, with shares climbing nearly 36% after the company announced a debt-to-equity conversion agreement with its primary lender, Streeterville Capital LLC. The move is designed to alleviate balance sheet pressure and help the sleep apnea device maker maintain its listing on the Nasdaq stock exchange.
The stock traded at $0.94 by early afternoon, up 35.7% from the previous close, after reaching an intraday high of $1.35. Trading volume surged to over 62 million shares, far exceeding the daily average. Despite the rally, the company's market capitalization remains modest at approximately $13.8 million.
Debt Conversion and Compliance Strategy
Under the terms of the agreement, Streeterville Capital will exchange up to $4.5 million of outstanding debt for a combination of perpetual, non-convertible preferred stock and common shares. The preferred stock ranks ahead of common equity in certain claims, but because it is non-convertible, it will not dilute common shareholders through conversion. In exchange, Streeterville has agreed to pause debt repayment demands for 90 days and suspend sales of Vivos securities for 60 days following the conversion.
The transaction is a critical component of Vivos' plan to restore compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2.5 million. As of December 31, 2025, the company reported negative stockholders' equity of approximately $1.55 million. The debt conversion, combined with a planned equity raise, is intended to boost stockholders' equity and address the Nasdaq deficiency notice received in April.
Risks Remain Despite Optimism
However, the deal is contingent on Vivos closing at least one qualifying equity financing that the company approves. Vivos has warned that it cannot guarantee the financing will occur or that any debt will ultimately be converted. This uncertainty leaves shareholders exposed to potential dilution if new equity is issued, as well as the risk of delisting if the exchange fails to materialize.
In its April filing, Vivos cautioned that a delisting would have a material adverse effect on its business, operations, and reputation. The company's stock has been under pressure for months, and the recent surge may reflect premature relief, as the path to compliance remains conditional.
Financial Performance and Business Shift
The balance sheet restructuring comes amid a broader transformation of Vivos' business model. In May, the company reported first-quarter revenue of approximately $5.1 million, a 70% year-over-year increase, driven by sleep-testing services and the June 2025 acquisition of The Sleep Center of Nevada. Despite the revenue growth, Vivos posted a net loss of $7.8 million for the quarter. As of March 31, the company held $2.1 million in cash and had a stockholders' equity deficit of $1.1 million.
CEO Kirk Huntsman stated in a May update that the Nevada acquisition and the shift in the business model "continues to drive patient volume and top-line revenue." He also noted that the company was actively working to "secure new funding" and "restructure our debt." The latest debt conversion agreement is a direct result of those efforts.
Market Context
Vivos' rally was company-specific and not part of a broader sector move. ResMed Inc. (NYSE: RMD) edged up 0.7%, while Inspire Medical Systems Inc. (NYSE: INSP) fell 1.7%. Small-cap stocks overall lagged, with the iShares Russell 2000 ETF (NYSEARCA: IWM) down 2.8% on the day.
Investors should note that the market's optimism may be premature. If new equity is issued, existing shareholders could see their stakes diluted. Moreover, Nasdaq's listing standards must still be satisfied, and the company's ability to secure the required financing remains uncertain. The next few weeks will be critical in determining whether Vivos can successfully navigate its compliance challenges.
